1. Home
  2. SLDB vs IMRX Comparison

SLDB vs IMRX Comparison

Compare SLDB & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Solid Biosciences Inc.

SLDB

Solid Biosciences Inc.

HOLD

Current Price

$6.62

Market Cap

444.9M

Sector

Health Care

ML Signal

HOLD

Logo Immuneering Corporation

IMRX

Immuneering Corporation

HOLD

Current Price

$5.38

Market Cap

366.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLDB
IMRX
Founded
2013
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
444.9M
366.1M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
SLDB
IMRX
Price
$6.62
$5.38
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
5
Target Price
$14.70
$17.20
AVG Volume (30 Days)
1.0M
3.1M
Earning Date
03-05-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.41
$1.10
52 Week High
$7.37
$10.08

Technical Indicators

Market Signals
Indicator
SLDB
IMRX
Relative Strength Index (RSI) 64.57 47.85
Support Level $5.26 $4.35
Resistance Level $5.96 $4.90
Average True Range (ATR) 0.41 0.60
MACD 0.13 0.01
Stochastic Oscillator 83.74 30.18

Price Performance

Historical Comparison
SLDB
IMRX

About SLDB Solid Biosciences Inc.

Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.

About IMRX Immuneering Corporation

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

Share on Social Networks: